Nho Kyushu Cancer Center

Fukuoka, Fukuoka 811-1395

0 studies enrolling now · 6 studies all time

What they study most

Advanced Malignancies, Advanced or Inoperable Gastric Cancer, Breast Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric, or Gastroesophageal Junction Adenocarcinoma

Studies at this site

• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies — Completed
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed
• Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer — Completed
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed